Global Veterinary Infectious Disease Diagnostics Market Trends and Insights
AI-Powered Image Analysis Adoption In Vet Labs
AI integration is moving laboratory interpretation from subjective, manual review to data-driven automation. Platforms such as Zoetis’ Vetscan Imagyst now screen lymph-node and skin-mass aspirates in minutes, a process that previously required days at external labs, enabling faster treatment decisions and improving client adherence. Nearly 30% of U.S. veterinarians already apply AI for imaging or record management tasks. Regulatory bodies, however, insist on rigorous validation before broad clinical use, promoting collaborative studies that benchmark AI accuracy against board-certified radiologists. Early adopters report sharper diagnostic confidence, a crucial benefit given the looming shortage of skilled practitioners. As reimbursements remain procedure-driven, AI tools that speed results without compromising quality are expected to shift from competitive advantage to baseline requirement, fuelling demand across the veterinary infectious disease diagnostics market.Advanced Diagnostic Devices For Animals
Multiplex PCR and cartridge-based POC systems are compressing test windows from days to minutes, helping clinics avoid follow-up visits and reduce antibiotic misuse. A 2025 triplex real-time PCR assay for swine respiratory diseases achieved 100% agreement with national standards, underlining molecular reliability. Zoetis’ Vetscan OptiCell extends this efficiency to complete blood counts in less than 10 minutes, offering reference-lab precision in-clinic. Genomic selection tools embedded within herd-health programs reduce disease susceptibility and antibiotic dependency, directly tying diagnostics to improved production metrics. Clinics that invest in such devices report higher client retention and the ability to charge premium service fees, reinforcing capital-investment cycles that sustain the veterinary infectious disease diagnostics market.Shortage of Skilled Veterinarians
The United States alone is projected to lack 70,092 veterinarians by 2032, with only 52,926 graduates expected, a gap driven by rural attrition and lifestyle preferences. Large-animal practice is hardest hit; livestock-focused vets have declined 90% since World War II, now representing under 2% of the profession. Fewer clinicians limit test ordering, especially in remote areas where mobile labs or tele-diagnostics must compensate. Technology that automates sample collection or streamlines interpretation partly offsets manpower gaps, but sustained shortages weigh on long-term volumes and slow expansion of the veterinary infectious disease diagnostics market.Other drivers and restraints analyzed in the detailed report include:
- Increasing Companion Animal Population
- One-Health AMR Surveillance Regulations
- High Pet-Care Costs
Segment Analysis
Immunodiagnostics retained a 43.78% revenue share in 2025 due to entrenched ELISA and chemiluminescent assays across routine screening. Nevertheless, molecular diagnostics recorded the quickest gains and are forecast to post a 10.07% CAGR, mirroring the broader shift toward precision medicine. Clinics adopting multiplex PCR report fewer inconclusive results and lower antibiotic misuse, boosting client confidence and strengthening loyalty within the veterinary infectious disease diagnostics market. Cartridges that integrate extraction and amplification simplify workflows, allowing smaller practices to perform formerly complex assays. Vendors further add AI-driven result interpretation, reducing error rates and training demands. Over the forecast window, integrated workstations that merge serology, PCR, and hematology functionalities are expected to dominate new-equipment purchases, underscoring the sector’s convergence trend.Market momentum also stems from next-generation sequencing (NGS) rollouts that enable pathogen discovery and AMR gene tracking. While cost per sample remains high, pooled testing strategies in herd health make NGS economically viable for high-value livestock operations. Cloud-based bioinformatics reduces on-premise infrastructure needs, fostering adoption across resource-constrained geographies. Immunodiagnostics will persist for high-throughput surveillance and cost-sensitive settings; however, their share is projected to decline gradually as rapid molecular platforms become ubiquitous across the veterinary infectious disease diagnostics market.
Companion animals generated 56.92% of global revenue in 2025, anchored by rising pet humanization and insurance uptake. Yet food-producing animals will expand fastest at 11.69% CAGR to 2031 as regulators impose stringent monitoring after incidents such as the H5N1 dairy-cattle outbreak that affected 989 U.S. herds. Livestock producers increasingly embed diagnostics in herd-health protocols to avoid culling losses and export bans. Governments subsidize surveillance kits, narrowing cost barriers and enlarging install bases for barn-side PCR readers, which, in turn, fuel the veterinary infectious disease diagnostics market size for this segment.
Genomic selection augments diagnostics by identifying disease-resistance alleles, reducing long-term medication costs and residue risks. Integrated platforms that merge pathogen detection with genetic profiling help producers comply with AMR-reporting mandates and sustainability certifications. Companion-animal growth will continue, albeit at a lower rate, as economic pressures spur selective testing behaviour. Clinics that offer bundled vaccination-plus-diagnostic packages should preserve volumes even in cost-sensitive markets, sustaining their position within the veterinary infectious disease diagnostics market.
Complete Report Scope:
- By Technology
- Immunodiagnostics (ELISA, CLIA)
- Molecular Diagnostics (PCR, RT-PCR, NGS)
- Rapid / Point-of-Care Tests
- Hematology & Clinical Chemistry
- By Animal Type
- Companion Animals
- Canines
- Felines
- Equines
- Food-Producing Animals
- Bovine
- Porcine
- Poultry
- Ovine & Caprine
- Companion Animals
- By Infection Type
- Bacterial
- Viral
- Parasitic
- Others
- By End User
- Reference Laboratories
- Veterinary Hospitals & Clinics
- Point-of-Care / In-house Testing
- Research Institutes & Universities
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America led the veterinary infectious disease diagnostics market in 2025 with 40.12% share due to mature veterinary infrastructure, high pet-insurance penetration, and robust livestock surveillance funding. Federal H5N1 mitigation programs drive continual demand for avian and bovine panels, sustaining consumable sales. Europe follows closely, characterised by stringent welfare rules and near-universal canine insurance in nations like Sweden, which support comprehensive diagnostic uptake. Pan-EU AMR directives also bolster molecular and genomic test adoption.Asia-Pacific stands out with the quickest 9.16% CAGR, fuelled by rising disposable incomes and rapid urbanisation in China, India, and Southeast Asia. Government-backed livestock modernisation programs require continuous pathogen monitoring, while middle-class pet owners increasingly demand Western-style preventive care, expanding the veterinary infectious disease diagnostics market. Partnerships with local distributors and price-tiered product lines are essential for penetration, given heterogeneous regulatory regimes and price sensitivity. Latin America, the Middle East, and Africa offer incremental growth via livestock disease-control initiatives and rising companion-animal ownership, but infrastructure limitations necessitate mobile-lab or satellite-network models to unlock full potential.
List of Companies Covered in this Report:
- IDEXX
- Zoetis
- Thermo Fisher Scientific
- bioMérieux
- Neogen
- Virbac
- Randox Laboratories
- INDICAL Bioscience
- ID Vet
- QIAGEN N.V
- Antech Diagnostics
- VCA Inc.
- GD Animal Health
- Eurofins Technologies
- QuidelOrtho (Vet Lab)
- Fujifilm Wako
- Mindray Bio-Medical (Vet)
- BioNote
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- IDEXX Laboratories
- Zoetis Inc.
- Thermo Fisher Scientific
- bioMerieux
- Neogen
- Virbac
- Randox Laboratories
- INDICAL Bioscience
- ID Vet
- QIAGEN N.V
- Antech Diagnostics
- VCA Inc.
- GD Animal Health
- Eurofins Technologies
- QuidelOrtho (Vet Lab)
- Fujifilm Wako
- Mindray Bio-Medical (Vet)
- BioNote

